(Q33688421)

28 July 2017

title

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit (English)

1 reference

28 July 2017

16

Razelle Kurzrock

1 reference

28 July 2017

17

Funda Meric-Bernstam

1 reference

28 July 2017

4

Filip Janku

1 reference

28 July 2017

11

Jaffer Ajani

1 reference

28 July 2017

author name string

Denis L Fontes Jardim

1

1 reference

28 July 2017

Debora de Melo Gagliato

2

1 reference

28 July 2017

Gerald S Falchook

3

1 reference

28 July 2017

Ralph Zinner

5

1 reference

28 July 2017

Jennifer J Wheler

6

1 reference

28 July 2017

Vivek Subbiah

7

1 reference

28 July 2017

Sarina A Piha-Paul

8

1 reference

28 July 2017

Siqing Fu

9

1 reference

28 July 2017

Mariela Blum Murphy

10

1 reference

28 July 2017

Chad Tang

12

1 reference

28 July 2017

Kenneth Hess

13

1 reference

28 July 2017

Stanley R Hamilton

14

1 reference

28 July 2017

Sinchita Roy-Chowdhuri

15

1 reference

28 July 2017

David S Hong

18

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 April 2014

1 reference

28 July 2017

1 reference

28 July 2017

volume

5

1 reference

28 July 2017

issue

7

1 reference

28 July 2017

page(s)

1837-1845

1 reference

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

A germline variant N375S in MET and gastric cancer susceptibility in a Chinese population

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Targeting MET in cancer: rationale and progress

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Ethnic differences and functional analysis of MET mutations in lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

A novel germ line juxtamembrane Met mutation in human gastric cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039117

30 October 2018

1 reference

12 December 2020

The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas

1 reference

12 December 2020

Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization

1 reference

12 December 2020

Gene amplification in gastric and esophageal adenocarcinomas

1 reference

12 December 2020

Gastroesophageal cancers: progress and problems

1 reference

12 December 2020

Identifiers

DOI

10.18632/ONCOTARGET.1828

0 references

PMC publication ID

4039117

1 reference

28 July 2017

1 reference